Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Inks China Point-of-Care Diagnostics Deal

NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has inked a cardiac point-of-care diagnostics alliance in China with Lepu Medical Technology, a medical device firm based in Beijing.

Under the deal, Lepu will market in China Qiagen's ESEQuant Lateral Flow System with five cardiac marker tests developed by Lepu intended to diagnose acute myocardial infarction. According to Qiagen, the system will be used in emergency rooms and the tests will be able to provide an accurate diagnosis within minutes at the point of care

China's State Food and Drug Administration has already approved the system with the tests, said Qiagen.

Lepu will market the system under the name Lepu Quant-Gold. Qiagen said that Lepu will initially receive 750 ESEQuant systems for China, but that number is expected to grow.

Qiagen acquired the ESEQuant system when it purchased German firm ESE for $19 million in early 2010. At the time, Qiagen said that the acquisition would open new opportunities in healthcare and applied testing for Qiagen, enabling low-throughput molecular testing in settings where a laboratory infrastructure is not accessible and fast turnaround is required.

Qiagen noted in its statement today that the China approval marks the first regulatory approval in human healthcare for the ESEQuant platform.

"This agreement advances two strategic initiatives," Frank Krieg-Schneider, head of global strategic alliances & OEM at Qiagen. "First, our geographic presence is further broadened by the addition of important point of need assays in China. China today represents Qiagen's third-largest country in sales. Secondly, we are driving platform success by launching ESEQuant as an SFDA-approved device in a lifesaving medical application, a milestone for our emerging point-of-need portfolio."

Financial and other terms of the alliance were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.